Nkgen Biotech Inc. · OTC:NKGN
Nkgen Biotech — AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases
20 slides from Nkgen Biotech's conference presentation, April 2025
Slide 1: Preliminary cognitive improvement in phase I cohort of moderate Alzheimer's Disease subjects
Preliminary cognitive improvement in phase I cohort of moderate Alzheimer’s Disease subjects treated with autologous natural killer cells (troculeucel; SNK01) Paul Y. Song, Lucia Hui, Hank Lee, Juan Mata, Katia Betito, Harry Chung, Jesse Carr Paul Y. Song. MD NKGen Biotech April 2025, Vienna, Austri
Slide 2: Disclosure of interest
No, Nothing to disclose X Yes, please specify Company / Honoraria / Consulting / Funded Royalties / Stock Ownership / Employee Other (Please Name Expense Advisory Research Patent Options Equity specify) Board Position NKGen Biotech X X
Slide 3: Natural Killer Cells
International Conference on ~ fh Alzheimer’s and Parkinson’s Diseases fa and Related Neurological Disorders #ADPL 5 | adpd.kenes.com wa 4 t Y ona i » Antleoeya Maat Tumor antigen Oe Cl NK va Tumor cell XC SH. ees cell = NCRL == omen WB au ty » Non-self MHC Activating KIRs
Slide 4: NKGen can expand NK cells from any donor
International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders #ADPD2025 | adpd.kenes.com NKGen can expand NK cells from any donor! Expansion Fold 8000 (8 Healthy Donors) s0e0 Expansion Average aun 08a cuture bay Expansion Fold (11 Cancer Patients) Average 2018 p
Slide 5: Autoreactive T cells Cause Neuroinflammation And Damage
International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders #ADPD2025 | adpd.kenes.com Autoreactive T cells Cause Neuroinflammation And Damage Chronic protein deposition leads to an autoinflammatory cascade and damage Removing proteins only addresses one aspec
Slide 6: Autoreactive T cells And SNK01 Cross BBB Via CXCR3
International Conference on a Alzheimer’s and Parkinson's Diseases AD/PD 2025 and Related Neurological Disorders VIENNA #ADPD2025 | adpd.kenes.com Autoreactive T cells And SNKOI Cross BBB (Blood Brain Barrier) Via GXCR3 ® SNKOI Has High CXCR3 Expression And Strong Migration Potential to cross the BB
Slide 7: NK Cells Regulate Autoreactive T cells
International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders #ADPD2025 | adpd.ken: NK Cells Regulate Autoreactive T cells'4 an SNKOI Has Enhanced NKG2D and DNAM-] Expression that helps identify and eliminate is autoreactive T cells to reduce auto-immune neuroin
Slide 8: SNK01 uptake of amyloid beta aggregates
International Conference on a Alzheimer’s and Parkinson’s Diseases AD/PD 2075 and Related Neurological Disorders VIENNA #ADPD2025 | adpd.ken: = a 33333 2 32333 soma Hab a [ comatens os 10 ge i zw Ba a) 3 3 5 2 0 ga 0 3 : 3 3 200 2 Be B wo ° 3 ra » 0 wet st asi ima pet ast we . 2th ash ‘Th nas mee 1
Slide 9: Zúñiga et al. Alzheimer's Research & Therapy (2025) 17:40
Zúñiga et al. Alzheimer’s Research & Therapy (2025) 17:40
Slide 10: NKGen Off-the-Shelf Autologous SNK Cell Therapy
International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders #ADPD2025 | adpd.ken: NKGen “Off-the-Shelf Autologous” SNK Cell Therapy Superior Cell Our Expansion and Cryoprocess Activation preserves cell features Auto-SNK No Lymphodepletion Collect Isolate Activ
Slide 11: ADCOMS change from baseline
International Conference on a Alzheimer’s and Parkinson’s Diseases AD/PD 2025 and Related Neurological Disorders VIENNA #ADPD2025 | adpd.ken: 5 ApH Grange ‘rom the beselne bean Raitiince Bailes Saimin) Hiatt . axo4-201-002 ADCOMS = a a 5 este s tne 03 fay sh msc Ata Dene (KAD AAD} : + waorae 5 on °
Slide 12: Study design: troculeucel IV Q3W in moderate AD
• Troculeucel IV Q3W, (3+3 dose escalation design - 6x109 cells), 17 doses • Moderate AD patients • Phase I followed by Randomized 2a (underway)
Slide 13: Methods
International Conference on rc ~ Alzheimer’s and Parkinson’s Diseases iD/PP poral and Related Neurological Disorders VIENNA #ADPD2025 | adpd.kenes.com Methods lOutcome | Baseline _| Week 14 | Week 26 | Week 38_| Week 50 (ET) | Primary endpoint Safety Xx xX Xx X xX Secondary endpoints Cognitive asses
Slide 14: Results - Safety (Primary outcome)
Results - Safety (Primary outcome) • Three patients enrolled at highest dose of 6 x 109 cells given every three weeks via IV for 17 treatments. • Three women – All with Moderate Stage Disease (CDR-SB score – 10.8, MMSE-20) • No drug-related adverse reactions for the 12-month study duration
Slide 15: Results – Cognitive Tests Change From Baseline
Results – Cognitive Tests Change From Baseline *MCID used to determine stable or improved cognition for CDR-SB = -2
Slide 16: Results – Cognitive Tests Change From Baseline
Results – Cognitive Tests Change From Baseline *MCIDs used to determine stable or improved cognition for ADAS-Cog = -3; ADCOMS = -0.1
Slide 17: Results – Neuroinflammation biomarkers
Results – Neuroinflammation biomarkers
Slide 18: Results – Protein biomarkers
Results – Protein biomarkers
Slide 19: Results – Protein biomarkers
Results – Protein biomarkers
Slide 20: Conclusions
Conclusions • Troculeucel (SNK01) was very well tolerated at the highest dose given to moderate AD subjects for 12 months • Preliminary efficacy evaluation • At 3 months, • 3 subjects showed stable or improved cognitive scores on CDR-SB and ADCOMS; • 2 of 3 subjects improved on all cognitive scales
NKGen Biotech — AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases on 6ix